SEC Comment Letter 0000000000-22-012891 to Cellectar Biosciences, Inc. (CLRB)
Cellectar Biosciences, Inc.
Date: Nov. 29, 2022 · CIK: 0001279704 · Accession: 0000000000-22-012891
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-268554
Letter
United States securities and exchange commission logo November 29, 2022 James Caruso President and Chief Executive Officer Cellectar Biosciences, Inc. 100 Campus Drive Florham Park, NJ 07932 Re:Cellectar Biosciences, Inc. Registration Statement on Form S-1 Filed November 23, 2022 File No. 333-268554 Dear James Caruso: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jason Drory at 202-551-8342 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Istvan Hajdu
Show Raw Text
United States securities and exchange commission logo
November 29, 2022
James Caruso
President and Chief Executive Officer
Cellectar Biosciences, Inc.
100 Campus Drive
Florham Park, NJ 07932
Re:Cellectar Biosciences, Inc.
Registration Statement on Form S-1
Filed November 23, 2022
File No. 333-268554
Dear James Caruso:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jason Drory at 202-551-8342 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Istvan Hajdu